quavonlimab,lenvatinib,favezelimab,pembrolizumab
eisai,merck
['keynote,495', 'keyimpact']
dr presents data on keynote-495/keyimpact phii trial showing positive survival results driven by biomarkers status (tmb and gep) and calls for more personalized immunotherapy approaches #sitc22 